JPRN-UMIN000015492招募中2 期
Rituximab combined with gemcitabine, dexamethasone, and cisplatin in elderly patients with relapsed or refractory diffuse large B-cell lymphoma - Rituximab combined with gemcitabine, dexamethasone, and cisplatin in elderly patients with relapsed or refractory diffuse large B-cell lymphoma (EDL-GDP)
ational Hospital Organization Kyushu Medical Center0 个研究点目标入组 42 人开始时间: 2015年1月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who fulfill any of the following criteria are not eligible for admission to the study: 1)B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (intermediate DLBCL/BL) or Burkitt lymphoma 2)Testicular lymphoma or central nervous system involvement by lymphoma. Patients diagnosed with CNS disease at the time of relapse (on-study) are not eligible. Patients diagnosed with CNS disease at initial presentation who achieved and maintained CNS CR at the time of relapse are eligible. Lumbar puncture must be done in this case prior to study entry to demonstrate CNS CR status. Tests to investigate CNS involvement are required otherwise only if clinically indicated. 3)Uncontrolled liver, kidney, cardiac or pulmonary dysfunction, or diabetes mellitus or hypertension. 4)Interstitial lung disease or pulmonary fibrosis. 5)Uncontrolled bacterial, fungal, or viral infection. 6)Patients with a history of cardiac dysfunction or cardiovascular disease (< 6 months at diagnosis). 7)Patients with a history of other malignancies, except: curatively treated in-situ cancer of the cervix, stomach, or colon, or other solid tumours curatively treated with no evidence of disease for > 5 years. 8)Positive for HBs-Ag, HCV-Ab, and/or HIV-Ab. 9)Drug hypersensitivity syndrome. 10) Patient is not able and willing to complete the consensus. 11)Other serious intercurrent illness or medical condition judged by the local investigator to preclude safe administration of the planned protocol treatment.
研究者
相似试验
进行中（未招募）
不适用
Intensive induction treatment with antibody therapy (Rituximab), chemotherapy (Ara-C) and steroids (dexamethasone) and bone marrow transplant in aggressive mantle cell lymphoma patients younger that 66 years.Mantle Cell LymphomaMedDRA version: 14.1Level: LLTClassification code 10026799Term: Mantle cell lymphoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004039-30-GBPLymouth Hospitals NHS Trust90
进行中（未招募）
不适用
Rituximab plus Bendamustine as front line treatment in frail elderly (=70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL)EUCTR2011-001421-24-ITFONDAZIONE ITALIANA LINFOMI ONLUS
进行中（未招募）
不适用
Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy.ntreated patients with follicular lymphoma in need of therapy.MedDRA version: 14.0Level: PTClassification code 10025310Term: LymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021253-39-SESwiss Group for Clinical Cancer Research SAKK152
进行中（未招募）
不适用
A comparison of two different treatments of patients with follicular lymphoma, i.e. the efficacy and tolerability of Rituximab in combination with a new drug (Revlimid) compared to the efficacy and tolerability of Rituximab alone .ntreated patients with follicular lymphoma in need of therapy.MedDRA version: 14.0Level: LLTClassification code 10059432Term: Follicular mixed small and large cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021253-39-FISwiss Group for Clinical Cancer Research SAKK152
进行中（未招募）
1 期
Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy.ntreated patients with follicular lymphoma in need of therapy.MedDRA version: 14.0Level: PTClassification code 10025310Term: LymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021253-39-DKSwiss Group for Clinical Cancer Research SAKK152